Skip to main content
. 2021 Sep 23;56(12):3049–3058. doi: 10.1038/s41409-021-01452-1

Fig. 2. Ixazomib treatment significantly decreases the T effector cells in pcGvHD model.

Fig. 2

Flow cytometry assays of the different organs at different time points after treatment were performed. A Percentage of effector (TEF/EM:CD44++CD62L) T cells were analyzed. B Percentage of CD8+ (SP), CD4+ (SP), CD4+ CD8+ (DP) and CD4CD8 (DP) in the thymus. Data are shown as mean ± SEM. Data are collected from 4–5 independent experiments with 5–6 mice per group. *P < .05, **P < .01, and ***P < .001. UTM: untreated transplanted mice (vehicle administration); IXZ: ixazomib group; HD: healthy donor; SYG: syngeneic group; 2/4 and +10 W: weeks after starting the treatment. P values were calculated using 1-way ANOVA and 2-sided Student’s unpaired t-test.